Pharmacokinetics and Recent FDA Approvals in Oncology

This chapter explores the pharmacokinetics of a new drug that is a substrate for the 3A4 enzyme and discusses its FDA approval for treating EGFR mutated non-small cell lung cancer. It also touches on the importance of dosage in oncology pharmacy and encourages community engagement.